Mar 4, 2020

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Dire

4 min
NORTH CHICAGO, Ill., March 3, 2020 /PRNewswire/ -- AbbVie i...

NORTH CHICAGO, Ill., March 3, 2020 /PRNewswire/ -- AbbVie issued the following forms today.

IRISH TAKEOVER PANEL


DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013


DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

 

1.  KEY INFORMATION

Name of person dealing (Note 1)

AbbVie Inc.   

Company dealt in

AbbVie Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

Common shares, par value $0.01 per share

Date of dealing

2 March 2020

 

2.  INTERESTS AND SHORT POSITIONS

(a)  Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)


Long

Short


Number


(%)

Number


(%)

(1) Relevant securities

N/A


(2) Derivatives (other than options)

N/A


(3) Options and agreements to purchase/sell

N/A


Total

N/A


 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:

Long

Short


Number


(%)

Number


(%)

(1) Relevant securities



(2) Derivatives (other than options)



(3) Options and agreements to purchase/sell



Total



 

3.  DEALINGS (Note 4)

(a)  Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Share buyback

1,149,900

$86.9413

 

(b)  Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (Note 5)





 

(c)  Options transactions in respect of existing relevant securities

(i)  Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)








 

(ii)  Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)




 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)




 

4.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.


 

Is a Supplemental Form 8 attached? (Note 9)

YES/NO√

Date of disclosure

3 March 2020

Contact name

Steven L. Scrogham

Telephone number

847-938-6166

Name of offeree/offeror with which acting in concert

AbbVie Inc.

Specify category and nature of acting in concert status

AbbVie Inc.

 

1.  KEY INFORMATION

Name of person dealing (Note 1)

AbbVie Inc.   

Company dealt in

AbbVie Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

Common shares, par value $0.01 per share

Date of dealing

3 March 2020

 

2.  INTERESTS AND SHORT POSITIONS

(a)  Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)


Long

Short


Number


(%)

Number


(%)

(1) Relevant securities

N/A


(2) Derivatives (other than options)

N/A


(3) Options and agreements to purchase/sell

N/A


Total

N/A


 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:

Long

Short


Number


(%)

Number


(%)

(1) Relevant securities



(2) Derivatives (other than options)



(3) Options and agreements to purchase/sell



Total



 

3.  DEALINGS (Note 4)

(a)  Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Share buyback

1,139,300

$87.7667

 

(b)  Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (Note 5)





 

(c)  Options transactions in respect of existing relevant securities

(i)  Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)








 

(ii)  Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)




 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)




 

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.


 

Is a Supplemental Form 8 attached? (Note 9)

YES/NO√

Date of disclosure

4 March 2020

Contact name

Steven L. Scrogham

Telephone number

847-938-6166

Name of offeree/offeror with which acting in concert

AbbVie Inc.

Specify category and nature of acting in concert status

AbbVie Inc.

 

Cision View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-301015976.html

SOURCE AbbVie

Share article

Subscribe to our Newsletter
Receive the latest updates and news
Exclusive preview
Array
Array
Array